On September 8, 2022 MaaT Pharma (EURONEXT: MAAT – the "Company"), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, reported that Hervé Affagard, CEO and co-founder of MaaT Pharma, and Siân Crouzet, CFO of MaaT Pharma, will participate in three upcoming investor conferences (Press release, MaaT Pharma, SEP 8, 2022, View Source [SID1234619253]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details for the events are as follow:
H.C. Wainwright 24th Annual Global Investment Conference (hybrid format)
Format: virtual presentation & investor meetings
Presentation date: Hervé Affagard will present the Company and provide a corporate update. The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7:00 am EST/1:00 pm CET on Monday, September 12, 2022. A replay will be available on the investor page of Maat Pharma’s website: View Source
Link: View Source
KBC Securities Life Sciences conference (virtual)
5th edition of the "FORUM Lyon Pôle Bourse Valeurs Régionales" (on-site event)